Melissa B, Epperly
Chief Financial Officer at Zentalis Pharmaceuticals, Inc. (ZNTL)
Melissa B, Epperly has filed 51 insider reports with the SEC since February 2021, as director at Roivant Sciences Ltd. (ROIV), director at Nautilus Biotechnology, Inc. (NAUT) and director at Kinnate Biopharma Inc. (KNTE) and at 1 more company. In the last 12 months Melissa B, Epperly sold $2.01M of stock on the open market. The latest filing, on September 18, 2026, reports grant or award at Roivant Sciences Ltd. (ROIV).
- Filings
- 51
- Companies
- 4
- Bought on market
- $500K
- Sold on market
- $4.68M
Companies where Melissa B, Epperly is an insider
| Company | Role | Shares held | Bought | Sold | Avg buy | Price now | Last filing |
|---|---|---|---|---|---|---|---|
| Directorsince June 2022 | 14,954 | $2.01M | $38.655 | Sep 18, 2026 | |||
| Directorsince June 2021 | $2.12 | Jun 22, 2026 | |||||
| Director | Apr 5, 2024 | ||||||
| Chief Financial Officer | 451,449 | $500K | $2.67M | $52.00 | $1.36-97% | Feb 13, 2024 |
Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record. Price now: the latest daily close, against the average buy price.
Every filing
- Sep 16, 2026ROIVDirector Epperly Melissa B, was granted 5,054 shares, increasing direct ownership by 51% to 14,954 unitsForm 4Grant or award
- Sep 15, 2026-$196KROIVDirector Epperly Melissa B, sold $196,230 worth of shares (4,938 units at $39.74) as part of a pre-agreed trading plan, decreasing direct ownership by 33% to 9,900 unitsForm 4Open-market sale10b5-1 plan
- Sep 10, 2026ROIVDirector Epperly Melissa B, covered exercise/tax liability with 2,179 shares, decreasing direct ownership by 13% to 14,838 units to satisfy withholding obligationForm 4Shares withheld for taxes or exercise price
- Jul 17, 2026ROIVDirector Epperly Melissa B, was granted 543 shares, increasing direct ownership by 3% to 17,017 unitsForm 4Grant or award
- Jun 29, 2026-$610KROIVDirector Epperly Melissa B, sold $610,252 worth of shares (17,750 units at $34.38) and exercised 17,750 shares at a strike of $4.46Form 4Exercise or conversion of a derivativeOpen-market sale
- Jun 18, 2026NAUTSEC Form 4 filed by Director Epperly Melissa B,Form 4Grant or award
- Apr 17, 2026ROIVSEC Form 4 filed by Epperly Melissa B,Form 4Grant or award
- Mar 16, 2026-$1.2MROIVSEC Form 4 filed by Epperly Melissa B,Form 4Open-market sale
- Jan 20, 2026ROIVDirector Epperly Melissa B, covered exercise/tax liability with 54 shares and was granted 815 shares, increasing direct ownership by 1% to 57,665 unitsForm 4Grant or awardShares withheld for taxes or exercise price
- Oct 20, 2025ROIVDirector Epperly Melissa B, was granted 1,056 shares, increasing direct ownership by 2% to 56,904 unitsForm 4Grant or award
- Sep 10, 2025ROIVDirector Epperly Melissa B, was granted 14,524 shares and disposed of $22,872 worth of shares (1,661 units at $13.77), increasing direct ownership by 30% to 55,848 unitsForm 4Grant or awardOther acquisition or disposition
- Jul 17, 2025ROIVDirector Epperly Melissa B, was granted 1,609 shares, increasing direct ownership by 4% to 42,985 unitsForm 4Grant or award
- Jun 23, 2025NAUTSEC Form 4 filed by Director Epperly Melissa B,Form 4Grant or award
- Apr 17, 2025ROIVDirector Epperly Melissa B, was granted 1,847 shares, increasing direct ownership by 5% to 41,376 unitsForm 4Grant or award
- Jan 23, 2025ROIVDirector Epperly Melissa B, was granted 1,672 shares and covered exercise/tax liability with 180 shares, increasing direct ownership by 4% to 39,529 unitsForm 4Grant or awardShares withheld for taxes or exercise price
- Oct 21, 2024ROIVDirector Epperly Melissa B, was granted 1,613 shares, increasing direct ownership by 4% to 38,037 unitsForm 4Grant or award
- Sep 12, 2024ROIVDirector Epperly Melissa B, disposed of $51,449 worth of shares (4,245 units at $12.12), decreasing direct ownership by 10% to 36,424 unitsForm 4Other acquisition or disposition
- Sep 10, 2024ROIVDirector Epperly Melissa B, was granted 16,406 shares, increasing direct ownership by 68% to 40,669 unitsForm 4Grant or award
- Jul 23, 2024ROIVDirector Epperly Melissa B, was granted 1,702 shares, increasing direct ownership by 8% to 24,263 unitsForm 4Grant or award
- Jun 14, 2024NAUTSEC Form 4 filed by Director Epperly Melissa B,Form 4Grant or award
- Apr 24, 2024ROIVEpperly Melissa B, was granted 1,146 shares and covered exercise/tax liability with 123 shares, increasing direct ownership by 5% to 22,561 unitsForm 4Grant or awardShares withheld for taxes or exercise price
- Apr 3, 2024KNTESEC Form 4 filed by Epperly Melissa B,Form 4Sale back to the company
- Feb 12, 2024-$29.4KZNTLEpperly Melissa B, sold $29,435 worth of shares (2,573 units at $11.44), decreasing direct ownership by 0.57% to 451,449 unitsForm 4Open-market sale10b5-1 plan
- Feb 2, 2024-$100KZNTLEpperly Melissa B, was granted 75,000 shares and sold $100,040 worth of shares (8,669 units at $11.54), increasing direct ownership by 17% to 454,022 unitsForm 4Grant or awardOpen-market sale10b5-1 plan
- Jan 19, 2024ROIVEpperly Melissa B, was granted 1,207 shares, increasing direct ownership by 6% to 21,538 unitsForm 4Grant or award
- Oct 16, 2023ROIVEpperly Melissa B, was granted 1,226 shares, increasing direct ownership by 6% to 20,331 unitsForm 4Grant or award
- Oct 4, 2023-$107KZNTLEpperly Melissa B, sold $106,926 worth of shares (5,482 units at $19.50), decreasing direct ownership by 1% to 387,691 unitsForm 4Open-market sale10b5-1 plan
- Sep 12, 2023ROIVSEC Form 4: Epperly Melissa B, was granted 17,825 shares, increasing direct ownership by 1,393% to 19,105 unitsForm 4Grant or award
- Jul 3, 2023ROIVSEC Form 4 filed by Epperly Melissa B,Form 4Grant or award
- Jun 15, 2023NAUTSEC Form 4 filed by Epperly Melissa B,Form 4Grant or award
- Jun 12, 2023KNTESEC Form 4 filed by Epperly Melissa B,Form 4Grant or award
- Feb 14, 2023-$158KZNTLSEC Form 4: Epperly Melissa B, sold $158,005 worth of shares (7,851 units at $20.13) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 392,048 units to satisfy tax liabilityForm 4Open-market sale10b5-1 plan
- Feb 1, 2023ZNTLSEC Form 4: Epperly Melissa B, was granted 101,957 shares, increasing direct ownership by 34% to 399,899 unitsForm 4Grant or award
- Oct 3, 2022ZNTLSEC Form 4: Epperly Melissa B, was granted 50,000 shares, increasing direct ownership by 20% to 297,543 unitsForm 4Grant or award
- Jul 20, 2022ROIVSEC Form 4 filed by Epperly Melissa B,Form 4Grant or award
- Jun 29, 2022ROIVMelissa B, Epperly became an insiderForm 3New insider
- Jun 15, 2022NAUTSEC Form 4 filed by Epperly Melissa B,Form 4Grant or award
- Jun 13, 2022KNTESEC Form 4 filed by Epperly Melissa B,Form 4Grant or award
- Apr 4, 2022-$856KZNTLSEC Form 4: Epperly Melissa B, sold $855,522 worth of shares (17,080 units at $50.09) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 247,414 units (for tax liability)Form 4Open-market sale10b5-1 plan
- Feb 23, 2022-$93.9KZNTLSEC Form 4: Epperly Melissa B, sold $93,921 worth of shares (1,913 units at $49.10) as part of a pre-agreed trading plan, decreasing direct ownership by 0.72% to 264,494 units (withholding obligation)Form 4Open-market sale10b5-1 plan
- Feb 10, 2022ZNTLSEC Form 4: Epperly Melissa B, was granted 16,405 shares, increasing direct ownership by 7% to 266,407 unitsForm 4Grant or award
- Oct 2, 2021ZNTLSEC Form 4: Epperly Melissa B, covered exercise/tax liability with 17,080 shares, decreasing direct ownership by 6% to 250,002 unitsForm 4Shares withheld for taxes or exercise price
- Aug 19, 2021+$500KZNTLSEC Form 4: Epperly Melissa B, bought $499,748 worth of Common Stock (9,611 units at $52.00), increasing direct ownership by 4% to 266,685 unitsForm 4Open-market purchase
- Jul 1, 2021-$158KZNTLSEC Form 4: Epperly Melissa B, sold $158,054 worth of Common Stock (3,083 units at $51.27), decreasing direct ownership by 1% to 257,074 unitsForm 4Open-market sale10b5-1 plan
- Jun 11, 2021KNTESEC Form 4 filed by Epperly Melissa B,Form 4Grant or award
- Jun 9, 2021NAUTSEC Form 3 filed by Epperly Melissa B,Form 3New insider
- May 3, 2021-$183KZNTLSEC Form 4: Epperly Melissa B, sold $182,635 worth of Common Stock (3,083 units at $59.24), decreasing direct ownership by 1% to 263,240 unitsForm 4Open-market sale10b5-1 plan
- Apr 5, 2021-$742KZNTLSEC Form 4: B, Melissa Epperly sold $742,323 worth of Common Stock (17,107 units at $43.39), decreasing direct ownership by 6% to 266,323 unitsForm 4Open-market sale10b5-1 plan
- Mar 1, 2021-$128KZNTLSEC Form 4: B, Melissa Epperly sold $128,482 worth of Common Stock (3,083 units at $41.67), decreasing ownership by 1% to 283,430 unitsForm 4Open-market sale10b5-1 plan
- Feb 11, 2021ZNTLSEC Form 4: B, Melissa Epperly was granted 15,000 units of Common Stock, increasing ownership by 6% to 286,513 unitsForm 4Grant or award
- Feb 1, 2021-$116KZNTLSEC Form 4: B, Melissa Epperly sold $115,805 worth of Common Stock (3,083 units at $37.56), decreasing ownership by 1% to 271,513 unitsForm 4Open-market sale10b5-1 plan
Compare Melissa B, Epperly with
- Melissa B, Epperly vs Keith S Manchester1 shared
- Melissa B, Epperly vs Daniel Allen Gold1 shared
- Melissa B, Epperly vs Frank Torti1 shared
- Melissa B, Epperly vs Matthew Gline1 shared
- Melissa B, Epperly vs Mayukh Sukhatme1 shared
- Melissa B, Epperly vs Richard Pulik1 shared
Other insiders at the same companies
- Jeffrey Evan HammerbacherROIV
- Keith S ManchesterROIV
- Daniel Allen GoldROIV
- QVT Financial LPROIV
- Frank TortiROIV
- Matthew GlineROIV
- Mayukh SukhatmeROIV
- Richard PulikROIV
- Eric VenkerROIV
- Ingmar BrunsZNTL
- Jennifer HumesROIV
- Ilan OrenROIV
- James C MomtazeeROIV
- Meghan FitzgeraldROIV
- Walters GroupZNTL
- Matthew L. PosardNAUT
Questions about Melissa B, Epperly
- What is Melissa B, Epperly's role at Zentalis Pharmaceuticals, Inc.?
- Melissa B, Epperly reports to the SEC as chief Financial Officer at Zentalis Pharmaceuticals, Inc. (ZNTL), according to the latest filing on February 13, 2024. Melissa B, Epperly has also filed as director at Roivant Sciences Ltd. (ROIV), director at Nautilus Biotechnology, Inc. (NAUT) and director at Kinnate Biopharma Inc. (KNTE).
- How many shares does Melissa B, Epperly own?
- After the latest filing that states it, Melissa B, Epperly directly owned 14,954 shares of Roivant Sciences Ltd. (ROIV) and 451,449 shares of Zentalis Pharmaceuticals, Inc. (ZNTL). Shares held through trusts, funds or family members are reported separately and are not counted here.
- Has Melissa B, Epperly bought or sold stock recently?
- The most recent open-market purchase was on August 19, 2021: bought 9,611 shares of Zentalis Pharmaceuticals, Inc. (ZNTL) for $500K at an average of $52.00. The most recent open-market sale was on September 15, 2026: sold 4,938 shares of Roivant Sciences Ltd. (ROIV) for $196K at an average of $39.74.
- How do I get alerts when Melissa B, Epperly files?
- Follow Melissa B, Epperly on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale. Melissa B, Epperly filed 3 times in the last 90 days.
From SEC Forms 3, 4, 5 and 144 filed by Melissa B, Epperly (SEC CIK 0001807359). Totals count each trade once, skipping amendments whose original is on file, from Feb 3, 2021 on. View on SEC EDGAR · Get this as JSON